Indirect comparison of apomorphine sublingual film and levodopa inhalation powder for Parkinson's disease ‘OFF’ episodes | Zendy

Andrew Thach | Zendy; Miriam L. Zichlin | Zendy; Noam Y. Kirson | Zendy; Karen Yang | Zendy; Katherine Gaburo | Zendy; Eric J. Pappert | Zendy; Darshan Mehta | Zendy; G. Rhys Williams | Zendy

Open Access

Indirect comparison of apomorphine sublingual film and levodopa inhalation powder for Parkinson's disease ‘OFF’ episodes

Author(s) -

Andrew Thach,

Miriam L. Zichlin,

Noam Y. Kirson,

Karen Yang,

Katherine Gaburo,

Eric J. Pappert,

Darshan Mehta,

G. Rhys Williams

Publication year - 2022

Publication title -

journal of comparative effectiveness research

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 0.567

H-Index - 23

eISSN - 2042-6313

pISSN - 2042-6305

DOI - 10.2217/cer-2021-0178

Subject(s) - medicine , parkinson's disease , levodopa , apomorphine , placebo , inhalation , anesthesia , rating scale , significant difference , disease , dopaminergic , psychology , dopamine , developmental psychology , alternative medicine , pathology

Aim: To compare efficacy of apomorphine sublingual film (APL) and levodopa inhalation powder (CVT-301) for ‘on-demand’ treatment of Parkinson's disease ‘OFF’ episodes. Patients & methods: Patient-level data from an APL pivotal study were re-weighted to match average baseline characteristics from a CVT-301 study (SPAN-PD). Placebo-adjusted treatments were compared at week 12. Results: Improvements in predose Unified Parkinson's Disease Rating Scale Part III scores were significantly larger for APL versus CVT-301 at 60 min postdose (least squares mean difference-in-difference: -8.82; p = 0.002); difference at 30 min favored APL but was not statistically significant (-4.46; p = 0.103). Total daily ‘OFF’ time reductions were significantly larger for APL versus CVT-301 (-1.31 h; p = 0.013). Conclusion: Results suggest APL treatment may lead to improved efficacy versus CVT-301.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research